Comparison of the lipopretein profiles and the effect of N-phenylpropyl-N-benzyloxy acetamide in primates (38473).
Analytical ultracentrifugation showed Cebus and Rhesus monkeys had two low density components while only one was present in Squirrel monkeys. In untreated or W1372 treated monkeys, neither chylomicrons nor very low density lipoproteins were detected on analytical ultracentrifugation. Chylomicrons were not observed on agarose gel electrophoresis. Ultracentrifugal analysis showed W1372 treatment decreased the amount of LDL in all animals and also the HDL in Cebus monkeys on an atherogenic diet. Both untreated and W1372 treated Cebus monkeys on an atherogenic diet had abnormal amounts of LDL and HDL, while the LDL in treated animals occurred as multiple peaks. This was also evident on agarose gel  electrophoresis. Accumulation of lipds in the liver and decrease of serum lipids indicated W1372 prevented release of lipoproteins from the liver.
D000081:Acetamides / Q000494:pharmacology; D000818:Animals; D001593:Benzyl Compounds / Q000494:pharmacology*; D002784:Cholesterol / Q000378:metabolism; D002914:Chylomicrons / Q000097:blood; D004036:Diet, Atherogenic; D004586:Electrophoresis; D006877:Hydroxamic Acids / Q000031:analogs & derivatives* / Q000494:pharmacology; D008074:Lipoproteins / Q000097:blood*; D008075:Lipoproteins, HDL / Q000097:blood; D008077:Lipoproteins, LDL / Q000097:blood; D008079:Lipoproteins, VLDL / Q000097:blood; D008099:Liver / Q000378:metabolism; D008251:Macaca; D013268:Stimulation, Chemical; D014280:Triglycerides / Q000378:metabolism; D014461:Ultracentrifugation
D000081:Acetamides; D001593:Benzyl Compounds; D002914:Chylomicrons; D006877:Hydroxamic Acids; D008074:Lipoproteins; D008075:Lipoproteins, HDL; D008077:Lipoproteins, LDL; D008079:Lipoproteins, VLDL; D014280:Triglycerides; D002784:Cholesterol